A Phase II Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Brain metastases; Breast cancer; Lung cancer
- Focus Therapeutic Use
- Acronyms CaBaMet
- 26 Jun 2017 Planned End Date changed from 1 Sep 2017 to 1 Apr 2018.
- 06 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2017.
- 06 Mar 2017 Status changed from recruiting to suspended because After a recruitment of more than 2 years, only 8 patients have been registered.